The safety, immunogenicity, and efficacy of a vaccine against cutaneous leishmaniasis in rural Ecuadorian children was assessed in a randomized, controlled, double-blinded study. Vaccine group subjects received 2 intradermal doses of a whole, killed promastigote vaccine cocktail plus bacille Calmette-Guérin (BCG) adjuvant. Control subjects got 2 doses of BCG only. The subjects who received both vaccination doses, 438 in the vaccine group (79.3%) and 406 in the control group (83.4%), were followed for 12 months. No serious adverse side effects were identified in either group. Significantly more vaccine group subjects than controls converted to a positive Montenegro skin test (85.1% vs. 20.1%; x 2 Å 279; P õ .001). The incidence of cutaneous leishmaniasis was significantly reduced in the vaccine compared with the control group (2.1% vs. 7.6%; x 2 Å 8.95; P õ .003). The protective efficacy of the vaccine was 72.9% (95% confidence interval Å 36.1% -88.5%).
Cutaneous leishmaniasis (CL) is a globally distributed para- [2, 17, 21] . For this reason, it remains unclear whether such vaccines can confer significant protection against the developsitic disease that causes unsightly topical ulcers and often results in permanent disfigurement. The disease is endemic ment of New World CL in humans. This evidence constituted the basis for the development of throughout most of the Americas [1 -3] ; recent estimates place the annual number of new CL cases in the region at 59,300, an antileishmaniasis vaccine by our research group in 1989. The development of the phenol-killed triple-strain parasite vacwith an additional 39.3 million persons reported to be at risk [3] . Cutaneous leishmaniasis is endemic in ú80% of provinces cine plus bacille Calmette-Guérin (BCG) adjuvant proceeded through a series of laboratory studies and small randomized, in Ecuador [4 -6] , with young children reported to be at particular risk for contracting the disease in many populations [5 -8] .
controlled, double-blinded clinical trials in nonsensitized human volunteers. These investigated various questions related Conventional disease control efforts in Ecuador [6] , as in most other Latin American nations, have had very limited success to the safety, immunogenicity, dosage level, and administration of the vaccine antigen [22, 23] . Subsequently, the results of a [2] . Thus, the development of a vaccine effective against New World CL would represent an important public health advance.
small randomized, controlled, and double-blinded pilot field study conducted in a population in which leishmaniasis is enThe body of data from experimental [9 -14] , clinical [15 -17] , and field studies [18 -20] suggest that vaccines based on demic suggested that the vaccine possessed an acceptable level of safety and immunogenicity. The disease incidence was 0 in killed whole, fractionated, or recombinant Leishmania promastigotes are nontoxic and possess immunogenic properties. Howthe vaccine group compared with 6% in controls during 1 year of follow-up [23, 24] . These favorable results led to the ever, the results of prior field studies have been difficult to interpret for various reasons that have been discussed recently undertaking of a larger phase III field study of the vaccine candidate. This article reports on the results obtained in the randomized, double-blind, placebo-controlled field trial of the vaccine in a high-risk child population during the first 12 negative MNST then underwent a clinical history and comprehensive physical examination. Children with evidence of current or fetal calf serum (Sigma), and 30 mg/L hemin (Sigma). The L. (L) amazonensis strain was harvested after 5 days of growth and the prior CL were excluded from further consideration, as were those with allergies, autoimmune diseases, other serious chronic condi-L. (V) braziliensis and L. (V) guayanensis after 6 days. Each strain was washed five times with PBS, counted, and added to a sterile tions, tuberculosis and other acute infections, or severe malnutrition defined as õ03 SD below the mean for weight-for-height. solution containing PBS plus 0.25% phenol. These were kept under refrigeration at 4ЊC. The strains were checked for viability by Children without evidence of present or past CL were defined as eligible for study participation. microscopy and culture. They also were each reviewed for sterility, nontoxicity, and innocuity. After passing these tests, the 3 strains
Vaccination procedure. The subjects were randomized to either the vaccine or control groups. The BCG adjuvant was reconstiwere combined to produce the final vaccine product. To accomplish this, 2. 8 promastigotes/mL. Subsequently, Ten 100-mL doses of this solution were withdrawn into coded disposable syringes, which were wrapped in an opaque material. the final product was again checked for parasite viability and sterility before being bottled into 10-dose sterile vials. The vaccine was Likewise, 10 doses of the BCG control solution were withdrawn into individual coded syringes wrapped with the same opaque kept under refrigeration until used, and any unused portions were discarded after 30 days.
material. Twenty subjects were vaccinated intradermally on the upper right deltoid with either the vaccine or placebo solutions (n BCG. The BCG used as the vaccine adjuvant (BCG, Tokyo) was reconstituted in its diluent and added to the vaccine just before Å 10 each) according to the randomization code. Depending on group assignment, 1 month after the first vaccination dose, the use. In addition, BCG was used as the control solution. Both of these preparations contained 5 1 10 5 viable organisms per injection subjects received a booster dose of either the vaccine or control solution administered to the upper left deltoid. The subjects and dose (100 mL), corresponding to the 1:2 dilution of normal dose of BCG used for vaccination against tuberculosis.
the study field personnel were blind to the subject coding scheme. Subject follow-up. The subjects were observed for 24 h after Montenegro skin test (MNST). The MNST antigen was produced under sterile conditions at the Immunology Research Laboeach vaccination dose to identify and treat any adverse side effects. Clinical evaluations were conducted 1 month after each vaccinaratory in Quito from the same Leishmania strains that were used in vaccine production. Equal parts of the 3 strains were combined tion for the purpose of detecting lymphadenopathy or other deleterious conditions and to examine the vaccination site for scarring, to produce a solution containing 100 mL of 6 1 10 6 phenol-killed promastigotes/mL. The MNST was administered intradermally.
redness, edema, induration, and ulceration. In addition, data were collected by interview from subjects and their parents regarding The results were measured and recorded 48 h later, and reactions having an induration of §5 mm were classified as positive.
any pain, itching, fever, malaise, anorexia, or other side effects that may have occurred during the prior month. One month after the Laboratory diagnosis of leishmaniasis. Direct smear and aspirate culture techniques were used to confirm the presence of Leishsecond vaccination dose, the subjects were administered another MNST and donated an 8-mL blood sample that was used in the mania amastigotes or promastigotes in subjects with suspicious lesions [5] .
determination of specific anti-Leishmania IgG and IgM serum antibodies. ELISA. The L. (V) guayanensis [MHOM/EQ/90/Juberly] antigen used in vaccine preparation also was used to measure the Subjects were followed by passive and active surveillance methods for 12 months after the second vaccination. Subjects and their specific anti-Leishmania serum antibody levels 1 month after the second vaccination dose. Specific anti-Leishmania IgG and IgM parents were instructed to report immediately to a local Ministry of Public Health health center that was affiliated with the study if serum antibody levels were quantified by use of an ELISA and were read with a Multiscan reader (Labsystems, Helsinki) set at they developed any dermal lesions that failed to heal promptly. Those reporting to the affiliated centers underwent a parasitologic 492 nm [5] .
Nutritional status. Weight, height, mid-upper arm circumferexamination to determine whether they had CL. In addition, community surveillance was done by the study team on a regular basis, ence, head circumference (in children aged õ24 months), and triceps skin fold measurements were taken from all subjects [25] . beginning 1 month after the first and second vaccination doses and every 6 months thereafter. During these visits, all subjects received Weight-for-height, height-for-age, and weight-for-age were compared with international growth reference standards by use of the a comprehensive physical examination that concentrated on the skin and mucous membranes. The size, placement, and characterisEpi Info 6.02 nutritional anthropometry program [26] .
Study area description. The study was done on a population tics of all dermal lesions and healed scars were inspected, measured, and recorded. Tissue samples were taken from subjects living in a rural subtropical rainforest area in which leishmaniasis is endemic in the northwest of Ecuador (Pichincha Province). The with suspicious lesions and evaluated parasitologically. Subjects diagnosed with CL received antimonial drug treatment. population incidence of CL in children during the 4 years before the study was estimated at Ç14% [5, 25, 27] (Armijos RX, unpubOutcome measures. The three major outcome measures of interest were vaccine safety, immunogenicity, and efficacy. Safety lished data). The Leishmania species identified as responsible for was measured as the absence of adverse (greater than grade 2) A total of 1042 subjects was randomized to either the vaccine (n Å 552; 53.1%) or control group (n Å 487; 46.9%). No significant differences were detected between the 2 experimental groups regarding compliance with the vaccination schedule.
15.8; P õ .0001), and there was a significant average increase of 5.9 mm in MNST size between baseline and 1 month after The 2-dose vaccine schedule was completed by 438 (79.3%) of the subjects in the vaccine group and 406 (83.4%) in the the final vaccination dose (mean Å 1.1 { 1.3 vs. 6.7 { 3 mm; t Å 32; P õ .0001). In contrast, the mean difference in precontrol group (x 2 Å 2.48; P ú .05). The characteristics of the subjects who received only 1 dose of the vaccine did not differ and post-MNST values of the control group was only 2.2 mm. Although this change was statistically significant (1.3 { 1.4 significantly at baseline from those who received the complete 2-dose course with respect to age, sex, ethnicity, nutritional vs. 3.4 { 3.4 mm; t Å 14.5; P Å .0001), it appeared to lack clinical importance, since 80% of the subjects remained status indicators, and mean MNST induration size. The prevaccination characteristics of subjects in the 2 experimental groups MNST-negative. The characteristics of the vaccine group subjects who converted to a positive MNST, or responders, were who completed both vaccination doses were comparable (table  1) . compared with those who continued to have a negative MNST, or nonresponders. However, MNST responders were not sigSafety. No severe systemic reactions were recorded in either experimental group. The most frequent side effects that nificantly different from nonresponders with respect to average age (mean Å 5.9 { 4.0 vs. 4.9 { 4.4 years), proportion of occurred after the first vaccination were local pain, swelling, and redness at the injection site, mostly confined to the initial females (16.8% vs. 13.1%), persons of mestizo ethnicity (97.5% vs. 96%), or nutritional status indicators, including 3 days. The most common side effects reported during the 1-month period after vaccination were ulceration, secretions, and mean weight (19.5 { 10.0 vs. 18.0 { 11.6 kg), height (105.2 { 27.1 vs. 96.9 { 29.6 cm), mid -upper arm circumference itching at the inoculation site (table 2) . No significant differences were found between the vaccine and control groups with (16.8 { 2.0 vs. 17.5 { 8.3 cm), triceps skin fold (9.0 { 3.5 vs. 7.6 { 2.1 mm), head circumference (44.3 { 3.1 vs. 44.6 respect to the proportion of subjects who experienced these side effects after the first and second vaccination. However, { 3.0 mm), and proportion with height-for-age (25.2% vs. 37.8%), weight-for-age (18.3% vs. 29.2%), and weight-forvaccine group subjects were more likely to report low-grade fever after the second vaccination (14.7%) than after the first height (11.2% vs. 15.8%) that were õ2SD below the mean according to international reference standards. (5.6%), a difference that was significant (x 2 Å 16.4; P Å .00005).
Mean specific anti-Leishmania IgG optical densities (ODs) measured 1 month after the second vaccination were signifiImmunogenicity. Significantly more subjects in the vaccine group than control group converted to a positive MNST 1 cantly elevated in the vaccine group compared with the control group (0.701 { 0.403 vs. 0.430 { 0.269; t Å 4.8; P Å .0001). month after the second vaccination (85.1% vs. 20.1%; x 2 Å 279; P õ .000001). Likewise, the average MNST induration
In contrast, the mean IgM ODs of subjects in the vaccine and control groups were comparable (0.508 { 0.323 vs. 0.481 { size was measurably higher in the vaccine group 1 month after the second dose (mean Å 6.7 { 3.0 vs. 3.4 { 2.5 mm; t Å 0.35; t Å 0.44; P ú .05). Vaccine efficacy. The incidence of CL in the vaccine group less ulcers that usually disappeared 6-8 weeks after vaccination. The only type of systemic side effects that could be linked to after the first 12 months was significantly lower than that in the control group (2.1% vs. 7.6%; x 2 Å 8.95; P Å .0028). vaccination were low-grade fever and microlymphadenopathy. However, these reactions affected only a small minority of subChildren who received the complete 2-dose vaccine had about only one-fourth the risk of developing the disease during the jects, and the proportions of these were comparable between groups. The low-grade fever was more common after the second first 12 months of follow-up compared with that in controls (odds ratio Å 0.27; 95% confidence interval Å 0.12 -0.64).
dose of the vaccine but responded readily to treatment with pediatric acetaminophen. Fever was not unexpected, since most vacThe protective efficacy of the vaccine was calculated at 72.9% (95% confidence interval Å 36.1% -88.5%).
cine booster doses in children typically induce such a response. Likewise, transient microlymphadenopathy that disappeared without treatment was detected in 11% of vaccine group and Discussion 14% of control group subjects. This also was anticipated, since all but a handful of children in the study already had received To our knowledge, this study is the first to report on the efficacy of a vaccine against New World CL consisting of one routine BCG vaccination at birth, and those aged §6 years had gotten an additional booster dose on their sixth birthday. killed whole promastigotes plus a BCG adjuvant. The results of the randomized, double-blinded, controlled field trial suggested However, despite repeated exposure to BCG, no cases of gross lymphadenopathy occurred in either experimental group. In addithat the vaccine was safe, immunogenic, and efficacious in preventing CL in Ecuadorian children for a 12-month period.
tion, the proportion of children who developed this mild form of ''BCG-itis'' was not greater after the second vaccination dose The randomization process appeared to be successful, since the sociodemographic, nutritional, and MNST characteristics of the than the first in either group. These side effects were comparable to those identified during our previous studies with the vaccine vaccine and control groups were not significantly different. The vaccine was well-received by the population, and there was a [22] [23] [24] . Furthermore, the type and severity of reactions were similar to those reported recently by Dowlati et al. [32] , who high level of compliance, Ç80%, in both experimental groups. This magnitude of compliance was exceptional, since many used various dosages of a Leishmania major-based vaccine plus BCG adjuvant. In fact, the reaction pattern seen in our current subjects and their families had to travel under adverse conditions to reach the study sites. The high observed compliance and prior studies was more characteristic of a response to BCG than to the Leishmania antigen itself. This hypothesis is supported reinforces the findings of recent KAP (knowledge, attitudes, and practices) studies conducted in the population in which indirectly by the evidence from studies of the L. amazonensiscontaining Leishvacin [33, 34] and other similar vaccines [18-many adults expressed a desire for a vaccine to prevent CL in children [27, 31] . Most subject loss during the study was caused 20] composed of killed whole-parasite promastigotes but that do not contain an adjuvant, all of which have fewer reported side by the out-migration of farmworker families to the Amazon or other areas of the country in search of improved economic effects.
In the vaccine group, average MNST size increased 6 mm prospects.
No severe adverse side effects were recorded during the course over prevaccination values. This was significantly higher than that observed for control subjects. In addition, only 15% of the of the study. Most of the vaccination-associated reactions were of a minor, local nature, the type, severity, and timing of which children in the vaccine group did not convert to a positive MNST, compared with 80% of controls. These data are in were not significantly different between the 2 experimental groups. In both groups, subjects typically developed small painagreement with observations in prior clinical studies [22, 23] and the pilot field trial [23, 24] . The postvaccination MNST it may have boosted cellular defenses through immunomodulatory action. There exists some evidence for BCG's immunobehavior of our vaccine was comparable to [21, 33] or improved over that reported for similar New World whole-parasite modulatory role. For example, inoculation with BCG has been reported to appear to confer protection against leprosy [38 -vaccines that did not contain any adjuvant [15, 18 -20] . Mean specific anti-Leishmania IgG serum antibody concentrations 40], an effect that may be enhanced by multiple doses [38, 39] . In addition, BCG treatment of BALB/c mice has been measured 1 month after the second vaccination were significantly higher in the vaccine than in the control group, although cited as reducing disease severity in animals infected with Leishmania tropica, Leishmania donovani, and L. major [41, those of IgM did not differ. This behavior of the latter, however, was not unexpected, since it is characterized by a rapid response 42]. Furthermore, it was found that animals given BCG 2 weeks before immunization with L. mexicana amazonensis resulted within days and it was measured after 1 month already had elapsed. In contrast, IgG responds more slowly. The antibody in protection against infection that was associated with a strong delayed hypersensitivity reaction [43] . Thus, if it is true that response finding is of interest, since even though increased humoral response to vaccination has been demonstrated in mice control subjects who were given BCG did not receive an inert placebo, then it is possible that the true efficacy of the vaccine [12] , the evidence from humans vaccinated with killed Leishmania promastigotes [15, 21] is not clear. Anti-Leishmania is higher. The possible immunomodulatory role of BCG in protection against CL should be investigated further in future antibodies have been linked with the presence of active disease in humans [5, 35] as well as with clinical severity indicators, studies.
In conclusion, the results indicate that the polyvalent vaccine such as lesion evolution time, lesion number [5, 35] , and lesion size [5, 36] . However, it is unknown whether antibody response plus BCG adjuvant tested in this field trial was safe, immunogenic, and efficacious in children living in an area of Ecuador to vaccination is associated with protection. It has been suggested that even if elicited, antibody response may be irrelevant in which CL is endemic. The 2-dose vaccine appeared to invoke a similar level of immune response and confer protection or that antibody levels may only be paralleling the activation of specific effector mechanisms required for a protective response.
against CL in children with mild to moderate malnutrition and in their better-nourished counterparts. These results suggest More detailed studies of vaccination-induced cellular and humoral immune response are required to better understand the that malnourished children should not be automatically excluded from participation in future trials of this and other antimechanism(s) by which the vaccine may confer protection.
The efficacy of the vaccine in the Ecuadorian child populaleishmaniasis vaccines. It remains to be answered how long the apparent protection conferred by the vaccine lasts. This tion measured at the end of the 12-month follow-up period was estimated at 73%. The results of previously published phase important issue will be answered in the near future, since after the data for the initial 12 months reported here were retrieved, III studies conducted in other New World populations investigating the prophylactic immunization of humans with killed the study was reblinded, and follow-up has continued for an additional 3 years. whole-promastigote vaccines without adjuvant are difficult to interpret regarding efficacy for various methodologic problems outlined recently [2, 21] . However, the performance of the
